HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd

Christian Fridolin Singer; Stephan Wenzel Jahn; Dominik Hlauschek; Ulrike Maria Heber; Charlotte Mang-Manger; Daniel Egle; Marija Balic; Angelika Pichler; Georg Pfeiler; Stephanie Kacerovsky-Strobl; Christoph Suppan; Magdalena Ritter; Edgar Petru; Richard Greil; Zsuzsanna Bago-Horvath; Christine Deutschmann; Günther Georg Steger; Michael Seifert; Florian Fitzal; Rupert Bartsch; Anu Santhanagopal; Jana Machacek-Link; Dalila Sellami; Magdalena Schwarz; Christian Fesl; Lidija Sölkner; Stephen Esker; Martin Filipits; Michael Gnant

doi:10.1002/cac2.12657

Cancer Communications ›› 2025, Vol. 45 ›› Issue (4) :428 -432. DOI: 10.1002/cac2.12657

LETTER TO THE JOURNAL

HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd

Author information +

¹. Department of Gynecology and Gynecological Oncology, Medical University of Vienna, Vienna, Austria

². Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

³. Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna, Austria

⁴. Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria

⁵. Department of Pathology, Medical University of Vienna, Vienna, Austria

⁶. Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria

⁷. Division of Clinical Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

⁸. Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

⁹. Department of Internal Medicine Hematology and Internal Oncology, LKH Hochsteiermark-Leoben, Leoben, Austria

¹⁰. Department of Gynecology and Obstetrics, Division of Gynecology, Medical University of Graz, Graz, Austria

¹¹. Department of Internal Medicine III, Paracelsus Medical University Salzburg, Salzburg, Austria

¹². Hanusch-Krankenhaus, Vienna, Austria

¹³. Department of General Surgery, Medical University of Vienna, Vienna, Austria

¹⁴. Global Oncology Medical Affairs, Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA

¹⁵. Research and Development, Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA

¹⁶. Center for Cancer Research, Medical University Vienna, Vienna, Austria

christian.singer@meduniwien.ac.at

Show less

History +

PDF

Cite this article

Download citation ▾

Christian Fridolin Singer, Stephan Wenzel Jahn, Dominik Hlauschek, Ulrike Maria Heber, Charlotte Mang-Manger, Daniel Egle, Marija Balic, Angelika Pichler, Georg Pfeiler, Stephanie Kacerovsky-Strobl, Christoph Suppan, Magdalena Ritter, Edgar Petru, Richard Greil, Zsuzsanna Bago-Horvath, Christine Deutschmann, Günther Georg Steger, Michael Seifert, Florian Fitzal, Rupert Bartsch, Anu Santhanagopal, Jana Machacek-Link, Dalila Sellami, Magdalena Schwarz, Christian Fesl, Lidija Sölkner, Stephen Esker, Martin Filipits, Michael Gnant, . HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd. Cancer Communications, 2025, 45(4): 428-432 DOI:10.1002/cac2.12657

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Lee J, Park YH. Trastuzumab deruxtecan for HER2+ advanced breast cancer. Future Oncol. 2022; 18(1): 7-19.

[2]	Hashimoto Y, Koyama K, Kamai Y, Hirotani K, Ogitani Y, Zembutsu A, et al. A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization. Clin Cancer Res. 2019; 25(23): 7151-7161.

[3]	Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022; 387(1): 9-20.

[4]	Krop EI, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K et al. Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). JCO. 2022; 40(16_suppl): 1002-1002.

[5]	Singer CF, Pfeiler G, Hubalek M, Bartsch R, Stoger H, Pichler A, et al. Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34). Eur J Cancer. 2020; 132: 43-52.